NCT03233438

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 91 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin Structure Infections)

Conditions

• Bacterial Infections
• Acute Bacterial Skin and Skin Structure Infection

Interventions

Type	Name	Description
DRUG	Dalbavancin	Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
DRUG	Usual Care	Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.

Timeline

• Start date: 2017-07-24
• Primary completion: 2018-10-30
• Completion: 2018-10-30
• First posted: 2017-07-28
• Last updated: 2020-01-18
• Results posted: 2020-01-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study